7,097 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Purchased by Verition Fund Management LLC

Verition Fund Management LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 7,097 shares of the biopharmaceutical company’s stock, valued at approximately $315,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $37,000. Quest Partners LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the period. CWM LLC raised its position in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth $146,000.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $60.00 to $56.00 in a report on Friday, September 27th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $56.33.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $38.97 on Friday. The stock has a market cap of $2.22 billion, a PE ratio of 3.43 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The stock has a fifty day moving average price of $50.02 and a 200 day moving average price of $46.64.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.